Skip to main content

Besim Ogretmen

FY2026 NIH rank #3,727
  • Program Leader
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 6475015Search this ID in NIH RePORTER
ORCID iD
https://orcid.org/0000-0002-1019-5660Verified identifier for this researcher
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Biochemistry

NIH Funding · FY2026

Linked Award Amount
$4.2M
Full award amounts, FY2026
Award Records
4
Records listing this PI
Award-Linked Rank
#3,727
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Besim Ogretmen. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

NCI

National Cancer Institute

$3.7M

3 awards · administering

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing Besim Ogretmen as a PI. Multi-PI records show the full award amount for context.

  • 5P30CA138313-18P30
    Medical University of South Carolina - Cancer Center Support Grant
    $2.2M
    award amount
  • 4R01CA285926-03R01
    Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancer
    $1.1M
    award amount
  • 1R01AG104132-01R01
    Determining the Link Between Alzheimer's Disease and Improved Anti-Cancer Immunity via Regulation of Mitochondrial Ceramide Metabolism in T-Cells
    $443.9K
    award amount
  • 5R01CA214461-09R01
    Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC
    $371.1K
    award amount

Award organization

Organizations that administered FY2026 awards listing Besim Ogretmen as a PI.

FY2026 award administered by Medical University of South Carolina (SC).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Medical University of South Carolina
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2025
    $2M Cumulative Funding
  5. 2025
    R01 Grant Holder
  6. 2025
    Program/Center Grant Leader
  7. 2026
    $5M Cumulative Funding
  8. 2026
    Entered Top 50% Nationally
    Ranked #3727
  9. 2026
    Entered Top 25% Nationally
    Ranked #3727